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Abstract
Background: Procedural pain relief is sub-optimal in neonates. Topical tetracaine provides pain
relief in children. Evidence of its efficacy and safety in neonates is limited. The objective of this study
was to assess the efficacy and safety of topical tetracaine on the pain response of neonates during
a venipuncture.
Methods:  Medically stable infants greater than or equal to 24 weeks gestation, requiring a
venipuncture, were included. Following randomization and double blinding, 1.1 g of tetracaine or
placebo was applied to the skin for 30 minutes. Participants received oral sucrose if they met local
eligibility criteria. The venipuncture was performed according to a standard protocol. A medium
effect size in the pain score (corresponding to about 2 point difference in the PIPP score) was
considered clinically significant, leading to a sample size of 142 infants, with 80% statistical power.
Local skin reactions and immediate adverse cardiorespiratory events were noted. The primary
outcome, PIPP score at 1 minute, was analysed using an independent Student's t-test.
Results: One hundred and forty two infants were included, 33 +/- 4 weeks gestation, 2100 +/- 900
grams and 6 +/- 3 days of age. There was almost no difference in PIPP scores at 1 minute between
groups (mean difference -0.09; 95% confidence interval [CI]: -1.68 to 1.50; P = . 91). Similarly, there
were no differences in PIPP scores during the 2nd, 3rd and 4th minute. Duration of cry did not differ
between the groups (median difference, 0; 95% CI, -3 to 0; P = . 84). The majority of infants in both
groups received sucrose 24%. Sucrose had a significant effect on the PIPP score, as assessed by an
ANOVA model (p = 0.0026). Local skin erythema was observed transiently in 11 infants (7 in the
tetracaine and 4 in the placebo group). No serious side effect was observed.
Conclusion: Tetracaine did not significantly decrease procedural pain in infants undergoing a
venipuncture, when used in combination with routine sucrose administration.
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Background
Neonates admitted to neonatal intensive care units
(NICUs) undergo multiple painful procedures during
their hospitalizations. The most prevalent of these proce-
dures is blood sampling either by heel lancing or veni-
puncture. Infants born prematurely experience an average
of 134 painful procedures within the first two weeks of life
or up to 14 painful procedures a day [1,2].
It is well established that neonates experience pain [3,4].
Pain is stressful and leads to behavioural and physiologic
disorganization, which in turn may lead to several long-
term consequences, including chronic pain and altered
neurobehavioral responses to subsequent pain [3]. Our
standard of care at the time this protocol was written was
to use non-pharmacological interventions including
swaddling and non-nutritive sucking for painful proce-
dures, such as venipuncture and heel pricks. Recently,
experts have recommended sucrose and/or local or sys-
temic analgesia before such procedures [5]. Side effects of
systemic analgesics limit their use on a regular basis [6,7].
EMLA (Lidocaine-Prilocaine 5% cream), a widely used
anesthetic cream, has a relatively long onset of action (60
minutes), can cause local blanching and vasoconstriction
and is associated with a theoretical risk of methemoglob-
inemia, which has been reported in infants in a few case
reports [8,9]. This can limit its usefulness in newborns.
Tetracaine gel (4% w/w tetracaine in an aqueous gel, Ame-
thocaine gel or Ametop, Smith-Nephew Inc, St-Laurent,
Quebec), a topical anesthetic developed in the early 1990s
acts by blocking the flux of sodium ions across the axon
and, thus, blocking the action potential. Due to its intrin-
sic properties, it appears to be a good option for new-
borns. First, its onset of action is only 30 to 45 minutes.
Second, it has no risk of methemoglobinemia. In addi-
tion, it causes local vasodilatation, which may be an
advantage in newborns as it can be a challenge to obtain
IV access or blood. Several trials involving older children
have demonstrated the efficacy of tetracaine in decreasing
pain associated with venipuncture, subcutaneous vaccina-
tion and Port-a-Cath puncture [10-16].
The localized anesthetic action of tetracaine has been
demonstrated in infants after 30 minutes [17]. Two rand-
omized controlled trials (RCTs) found a decrease in pain
scores and in duration of cry in infants who received tet-
racaine before a venipuncture or a venous catheter inser-
tion, however only 80 infants in total were enrolled and
very low birth weight (VLBW) infants were not included
[18,19]. No benefit was found for heel pricks or peripher-
ally inserted central catheter in a similar population in
four other randomized trials [7,20-23].
The evidence regarding safety and efficacy of tetracaine in
infants is limited by small numbers of infants enrolled in
trials and exclusion of VLBW infants. The objective of this
study was to evaluate whether the application of tet-
racaine 4% before a venipuncture in newborn infants
would safely and significantly decrease procedural pain as
compared to placebo.
Methods
Participants
Infants admitted to the Neonatal Intensive Care Unit
(NICU) of The Ottawa Hospital, General Campus (25 bed
level 2–3 unit) or The Children's Hospital of Eastern
Ontario (20 bed level 3a unit), Ottawa, Canada between
January 2003 and December 2004 were eligible for this
study if they required venous blood work. Infants were
enrolled if they met the following inclusion criteria: (1)
born at ≥ 24 weeks gestation, (2) skin considered in good
condition (no burns or rash), (3) if < 27 weeks gestation,
at least 48 h of life and (4) considered stable by the
attending neonatologist.
Eligibility criteria
Infants were excluded if they met any of the following cri-
teria: (1) skin considered immature (insensible water
losses requiring more fluids than usual for gestation), (2)
suspected or proven significant central nervous system
anomaly, (3) receiving opioids or sedatives at time of ven-
ipuncture or in the previous 12 hours or receiving muscle
relaxants, (4) facial anomalies (cleft lip, Moebius syn-
drome) preventing typical facial expression of pain or (5)
sub-optimal hepatic function (ALT > 2× upper normal
limit) or sub-optimal renal function (urine output < 1 ml/
kg/hour in the 12 hours prior to the research interven-
tion).
The study protocol was approved by the Research Ethics
Boards of The Ottawa Hospital and the Children's Hospi-
tal of Eastern Ontario. Written informed consent was
obtained from a parent or legal guardian for all enrolled
infants.
Intervention
Under the supervision of the research assistant, the study
gel was applied to the proposed venipuncture site 30 min-
utes prior to the venipuncture, by a nurse 'blind' to group
assignment. Tetracaine 4% gel was applied to the skin of
each participant allocated to the treatment group; Profes-
sional Care Lotion (by Smith-Nephew), a skin moisturizer
was applied to the skin of each participant allocated to the
placebo group. An occlusive dressing (sterile Saran Wrap)
was applied over the gel. Tubes of 1.5 g of tetracaine were
used, of which 1.1 g could be extracted; the dose of gel
applied to the skin was therefore 1.1 g. After 30 minutes,
the gel was removed and the venipuncture began.BMC Pediatrics 2007, 7:7 http://www.biomedcentral.com/1471-2431/7/7
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Blinding
The study gels were packaged by a single research pharma-
cist in identical looking ointment jars identified by medi-
cation numbers, which matched the enrolment numbers.
Both gels were white, odorless and had the same consist-
ency. Pre-prepared jars containing tetracaine 4% or pla-
cebo gel identified by the medication numbers were sent
to the NICUs and stored in a climate-controlled refrigera-
tor. Once a participant was enrolled, the next sequential
jar was used for the venipuncture. The parents, guardians
and research team, including outcome assessors, were
blind to treatment assignment throughout the study. The
success of our blinding procedure was not assessed.
Randomization
Infants were randomized having equal probability (1:1)
of being allocated to either placebo or tetracaine 4% gel.
Since the infants' gestational age and maturity varied
across the two NICUs, the randomization was stratified by
centre. The sequence, a random-permuted block with
block size of 4, was computer generated by the study stat-
istician. To help ensure adequate allocation concealment,
the sequence was kept centrally on computer and could
only be activated when there was an eligible baby to ran-
domize. Only the research pharmacist was aware of the
randomization code. The randomization sequence was
not broken until data analysis was completed.
Co-interventions
Where possible, both groups received standard, currently
practiced non-pharmacological measures of non-nutritive
sucking, swaddling and comforting throughout the proce-
dure, as appropriate for gestation. Between the time the
study protocol was written and funded and the beginning
of the trial, it became standard policy in both NICUs that
infants undergoing painful procedures receive oral
sucrose 24% before such procedures, depending on gesta-
tional age and ability to feed. Withholding the standard of
care for study patients is unethical, thus infants enrolled
in the trial received sucrose if they met sucrose eligibility
criteria: 260 to 326 weeks receiving minimum 50% of oral/
enteral feeds, > 32 weeks receiving any amount of oral/
enteral feeds, infants on full feeds regardless of gestational
age, suck and/or swallow reflex present and if intubated,
ventilator rate < 20/minute. Sucrose 24% was adminis-
tered in doses of 0.1 to 0.5 cc depending on gestational
age.
Procedure
The study gel was applied and removed by the nurse (bed-
side or clinical/team leader) performing the blood work.
S/he was unaware of group allocation of the infant. The
blood work was performed according to a standardized
protocol.
Data was collected during 5 phases of the venipuncture: 1)
Application phase – the nurse examined the skin. S/he
applied the study gel to the appropriate venipuncture site
and an occlusive dressing (sterile Saran wrap) was applied
over the site. After 30 minutes the dressing and the gel
were removed. 2) Baseline – The infant remained undis-
turbed in a position of comfort for 1 minute. 3) Prepara-
tion – The skin was cleansed with an alcohol or a
chlorhexidine swab. 4) Venipuncture – Skin puncture was
performed with a #25 gauge Butterfly, using a tourniquet.
Bloodwork was performed on the dorsum of the hands or
feet or antecubital area. 5) Recovery – The infant was
returned to a position of comfort at which point filming
ceased.
A maximum of three attempts (at the same site) were
allowed before the procedure was stopped and declared
unsuccessful.
Physiological indicators of pain (heart rate, blood pres-
sure, respiratory rate, oxygen saturation) were continu-
ously recorded using a Hewlett Packard Neonatal monitor
for the phases of recording.
The Research Assistant videotaped facial action indicators
from baseline to the end of the recovery phase with a Sony
8 mm digital Camcorder. The total duration of cry from
skin puncture to recovery was determined from the video
camera recordings. All data was entered on a personal dig-
ital assistant and subsequently uploaded on to a central
database.
Outcomes
Efficacy
The primary outcome was the Premature Infant Pain Pro-
file (PIPP) score in the first minute after skin puncture.
The PIPP is a tool that was specifically developed to assess
acute pain in preterm and term infants [24]. It has under-
gone extensive clinimetric development for procedural
pain of heel-stick, venipuncture, intravenous insertion
and circumcision. Interrater and intrarater reliability anal-
ysis for individual event scores yielded coefficients of 0.93
to 0.96 and 0.94 to 0.98, respectively [24].
One of two trained facial coders from Dr. Bonnie Stevens'
laboratory at The Hospital for Sick Children in Toronto
assessed the video camera recordings of the venipuncture
for three specific validated facial expressions of pain
which are part of the PIPP score: brow bulge, nasolabial
furrow and eye squeeze. The intrarater and interrater reli-
ability scores of the facial coders were 0.95 and 0.95 (per-
cent agreement) respectively during the study. Coders
were blind to the group allocation of the infants. One
investigator (DH) calculated PIPP scores every minute,
from baseline to the recovery phase, by combining theseBMC Pediatrics 2007, 7:7 http://www.biomedcentral.com/1471-2431/7/7
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behavioral findings to the other components of the PIPP.
Each PIPP score was derived by calculating two 30-second
intervals for each minute of the procedure. The PIPP score
was assigned as the highest value of the two 30 second
scores.
The secondary outcome measures were: (1) PIPP scores
during the second, third and fourth minute of the inser-
tion phase (compared both independently and longitudi-
nally including the observationduring the first minute of
the procedure) (2) mean heart rate in beats per minute,
mean respiratory rate per minute, mean blood pressure in
mm Hg and mean O2 saturation in % at the end of base-
line, 1 minute after skin puncture then 2, 3, 4, 5 and 10
minutes after skin puncture (3) duration of cry, from skin
puncture to recovery (4) mean number of attempts
required to obtain the blood work, success rate at obtain-
ing the blood work and subjective measure of easiness on
a scale of 1 to 5 (1 being very easy and 5 very hard). Ease
of procedure was derived by asking the nurse to appraise
his/her assessment of the ease of obtaining bloodwork.
Harms
The safety of tetracaine was appraised using the following
data: local skin reaction (redness, oedema), complete
blood count and differential (pre and post intervention),
AST and ALT (pre and post intervention), and creatinine
levels (post intervention). Blood work (0.8 cc) was col-
lected along with clinically indicated (by the treating
team) blood tests, within 72 hours of the intervention and
then again, 48 to 72 hours after the intervention. There is
no previously reported blood safety data on tetracaine in
neonates and so we monitored the function of important
organs (bone marrow, liver, and kidney). All infants' vital
signs were monitored throughout and after the interven-
tion and any significant event (apnea/bradycardia [respi-
Participant flow through the study Figure 1
Participant flow through the study.
Assessed for eligibility
(n=339)
Randomized (n=142)
Excluded (n=197):
. Parent declined consent (n=105)
. Did not meet eligibility criteria (n=23)
. Missed patients (n=69)
Allocated to tetracaine
(n=71)
Allocated to placebo (n=71)
Included in the analysis
(n=68)
Included in the analysis
(n=69)
.Technical difficulties with
cardiac monitor (n=2)
.Technical difficulties with
video recording (n=1)
.Technical difficulties with
cardiac monitor (n=2)BMC Pediatrics 2007, 7:7 http://www.biomedcentral.com/1471-2431/7/7
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ratory pause of >20 seconds with consequent decrease in
heart rate < 80], sustained bradycardia or tachycardia, sus-
tained desaturation requiring intervention) was recorded.
Statistical analysis
The sample size calculations were based on the following
assumptions: i) a medium effect size of 0.50 (based on
local agreement of clinicians as being clinically significant
and based on previous literature); ii) statistical power of
80% and iii) a (2-sided) type I error of 5%. Considering a
standard deviation of 4.7, a medium effect size would
translate into a difference in PIPP score of 2.35 units. To
account for technical or equipment problems, 10% was
added to the sample size, thus 142 patients (71 per group)
were required.
One planned interim analysis was conducted after half of
the patients were enrolled. This analysis focused on the
primary outcome and safety issues. Using the O'Brien-
Fleming criteria for two-sided test, the alpha-level of this
interim analysis was 0.005. The final analysis was con-
ducted using a type one error of 0.048. The interim analy-
sis did not reveal any statistically significant findings.
Descriptive statistics of baseline data for both groups were
summarized. Pain scores were computed for every minute
during the venipuncture. Difference in mean PIPP score
during the first 4 minutes between treatment groups was
assessed using independent Student's t-tests.
Differences between treatment and control groups in PIPP
scores assessed over the first 4 minutes was compared
using an analysis of variance (ANOVA) for repeated meas-
ures, adjusting for gender, postnatal age, use of sucrose
and interaction between sucrose and treatment group.
These variables may influence the expression of pain in
infants [25,26].
Changes in physiological pain parameters such as heart
rate, respiratory rate, and blood pressure were summa-
rized using descriptive statistics. A log-rank test was used
to assess whether or not the duration of cry was different
for the group receiving tetracaine and the placebo group.
Differences in number of attempts to obtain the blood
work were determined using a Mann-Whitney test. For
safety comparisons, descriptive statistics of local skin reac-
tion, anomalies on the CBC, liver or renal function tests
for each group were summarized and compared using
Fisher's exact test.
Results
Infants were recruited for the study between January 2003
and December 2004. Three hundred and thirty nine
infants were assessed for eligibility during that time. (Fig
1) 197 were excluded. Excluded infants were more mature
and larger than included infants. (Table 1) This reflected
the fact that more mature infants required minimal blood
work. In total, 142 infants were randomized. Gestational
age ranged from 240 to 414 week and birthweight from
556 to 4860 g. In five cases, problems with either the
video recordings or the monitoring equipment precluded
assignment of a primary outcome. Primary outcome was
assessed in 137 infants (69 in the tetracaine and 68 in the
placebo group).
Baseline characteristics of infants enrolled in the study
were similar between groups (Table 2). The mean PIPP
score in the first minute was 7.71 in the tetracaine group
as compared to 7.62 in the placebo group (p = 0.909). No
significant differences in PIPP scores during the 2nd, 3rd
and 4th minutes were observed between the groups (Table
Table 1: Characteristics of excluded and included patients
Characteristics Excluded (n = 174) Included (n = 142) Difference (95%CI) P-value
Birth weight in gms, mean 
(sd)
2475.98 (961.41) 2123.68 (951.74) 352.30 (139.34, 565.26) 0.001
Completed weeks of 
gestation, mean (sd)
35.10 (3.61) 33.21 (4.08) 1.89 (1.04, 2.74) <0.001
Male, n (%) 90 (51.7) 85 (59.9) -8.1 (-18.8, 2.9) 0.172
Table 2: Baseline characteristics
Characteristics Placebo (n = 71) Tetracaine (n = 71)
Birth weight in gms, mean (sd) 2116.14 (966.60) 2131.21 (943.47)
Completed weeks of gestation, mean (sd) 33.04 (4.28) 33.37 (3.89)
Male, n (%) 43(60.6) 42 (59.2)
Age in days, mean (sd) 6.58 (3.01) 6.77 (3.25)
Sucrose received (n) 58 54BMC Pediatrics 2007, 7:7 http://www.biomedcentral.com/1471-2431/7/7
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3). Median duration of cry in non-intubated infants was 5
seconds (tetracaine group) versus 0.5 seconds (placebo
group) (p = 0.837). Additionally, 37 (57.8%) infants cried
in the tetracaine group compared to 33 (50.0%) in the
placebo group. Ease of venipuncture, number of attempts
and success rates were similar between the groups (Table
3). Mean heart rate, respiratory rate, saturation and mean
blood pressure at the end of baseline, 1, 2, 3, 4, 5, and 10
minutes were similar between groups (data not shown).
Previous RCTs suggest that local anaesthesia (EMLA) may
not add further benefits to oral sucrose/glucose when
used prior to a venipuncture [25,26]. We therefore con-
ducted a post-hoc analysis of the primary outcome, strati-
fied by use of sucrose (Fig 2). Fifty-four infants in the
treatment group and 58 in the placebo group received
sucrose. The repeated measures ANOVA, adjusted for gen-
der, postnatal age and use of sucrose, indicated that use of
sucrose was the only significant factor (p = 0.002) contrib-
uting to the variance in PIPP scores in the first 4 minutes
of the intervention. PIPP scores were similar in infants
who received sucrose, whether or not they also received
tetracaine (interaction term p-value = 0.545).
Transient skin erythema was observed in 7 infants in the
tetracaine group and in 4 infants in the placebo group (p
= 0.532). No serious skin reaction was observed in either
group. No significant changes were noted in any patients'
CBC, ALT or creatinine in either group (data not shown).
No significant adverse event was noted throughout the
study. One infant in the placebo group died of fulminant
necrotizing enterocolitis eight hours after randomization.
After careful review of the event, the data safety monitor-
ing committee and Health Canada concluded that this
serious adverse event was unrelated to the study.
Discussion
Topical tetracaine appeared safe but did not significantly
decrease procedural pain in this group of preterm and
term infants undergoing venipuncture. We had sufficient
statistical power to observe a moderate effect size (differ-
ence of 2.35 on the PIPP score) between the treatment
groups. Despite the statistical result, we believe our results
are important clinically, for those looking after preterm
and term infants requiring bloodwork.
To our knowledge, our study is one of the largest reported
that includes preterm and term infants receiving tet-
racaine. Our results conflict with previous randomized tri-
als using tetracaine for pain relief during venipuncture in
newborns. For example, Jain et al, in a RCT that included
40 preterm and term infants reported a significant
increase in the proportion of infants experiencing little or
no pain (from 30% to 84%) during a venipuncture in the
group receiving tetracaine, as compared to placebo [18]. A
validated adaptation of the neonatal facial coding system
and duration of cry were used to assess pain. This tool
took into consideration only the facial expression of pain
and the designation of little or no pain was made arbitrar-
ily. Moore reported lower pain scores in the group that
received tetracaine prior to venous cannulation in a RCT
that included 40 preterm and term infants [19]. An unval-
idated pain tool derived from several validated pain tools,
which included facial expression, cry, heart rate and ease
of cannulation was used. Our results are difficult to com-
pare to other trials, as the pain tool and concomitant use
of non-pharmacological pain interventions differed.
There are several explanations and limitations that could
account for the statistically null results. Like other trials
exploring ways to minimize pain in infants, this study was
Table 3: Study outcomes
Outcome n Placebo n Tetracaine Difference (95% 
CI)
p-value
PIPP, 1st minute, 
mean (sd)
68 7.62 (4.76) 69 7.71 (4.66) -0.09 (-1.68, 1.50) 0.909
PIPP, 2nd minute, 
mean (sd)
53 6.45 (4.32) 51 6.84 (4.42) -0.39 (-2.09, 1.31) 0.650
PIPP, 3rd minute, 
mean (sd)
25 8.44 (4.37) 26 5.96 (4.67) 2.48 (-0.07, 5.03) 0.056
PIPP, 4th minute, 
mean (sd)
12 8.17 (5.08) 14 5.29 (5.10) 2.88 (-1.25, 7.01) 0.163
Duration of cry in 
seconds, Median 
(range)
66 0.5 (0, 175) 64 5 (0, 159) 0 (-3, 0) 0.837
Ease of insertion, 
median (range)
71 2 (1, 5) 71 1 (1, 5) 0 (0, 0) 0.456
Number of 
attempts
71 1 (1, 2) 71 1 (1, 2) 0 (0, 0) 0.414
Venipuncture 
successful, n (%)
71 36 (50.7) 71 46 (64.8) -14.1 (-29.3, 2.1) 0.126BMC Pediatrics 2007, 7:7 http://www.biomedcentral.com/1471-2431/7/7
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subject to potential problems related to the use of assess-
ment processes and tools. Manually coding the videotapes
and pain assessment is likely open to human error.
Although measures were taken to decrease the chance of
error, specifically, conducting random calibration exer-
cises to verify the PIPP scores and testing interrater and
intrarater reliability during the study, some margin of
error remained. Likewise, the PIPP tool continues to
undergo clinimetric testing and might result in refinement
to its use and/or coding in the future.
The recommended dose and duration of application of
tetracaine was used. Immature infants whose skin techni-
cally could absorb more medication rather than less
would be expected to respond to the drug. Stability of the
drug once removed from its original packaging has not
been clearly established. We followed the manufacturer's
recommendation at the time (and did not use the drug
past 28 days after removal from its original package) (per-
sonal communication, Jason Collins, December 2002). As
it becomes inactive, tetracaine crystallizes. We did not
observe or feel crystals in the study gel during the trial.
Another limitation of this study is that we did not stratify
according to the use of sucrose due to the timing of imple-
mentation of our oral sucrose guidelines. Sucrose has
been shown to have a definite impact on the pain experi-
enced during heel pricks and venipunctures in newborns
25 to 41 weeks gestation up to 28 days of age [26]. Given
the proven benefits of sucrose, we felt it would have been
unethical not to allow study infants to receive sucrose if
they met the eligibility criteria, as infants not included in
the study would have received it as standard of care.
A randomized trial comparing water, sucrose 24%, EMLA
and EMLA with sucrose 24% in term newborns undergo-
ing a venipuncture found that sucrose compared favoura-
bly with EMLA [27]. The concomitant use of EMLA did
not increase further the analgesic efficacy of sucrose. In
another RCT, glucose 30% was as effective as EMLA to
decrease procedural pain in newborns undergoing veni-
puncture, as assessed by the PIPP [28]. Our own findings,
along with those from these previous trials lead us to spec-
ulate that sucrose had an important impact on the pain
scores in our study. These were confirmed by our post-hoc
analysis, which showed that sucrose was the only signifi-
cant factor included in the regression analysis contribut-
ing to the variance in PIPP scores in the first 4 minutes of
the intervention. It is possible that sucrose was as effective
as tetracaine at reducing procedural pain, but this remains
a hypothesis, as our study design does not permit us to
conclude this.
Several nurses, with varying degrees of experience, were
involved in performing the venipunctures adding to the
generalizability of our findings. However, given the sam-
ple size, this may have contributed to the lack of differ-
ence in the number of attempts and ease of procedure and
possibly to the relatively low success rates of the venipunc-
ture. Similarly, we included infants of all gestations, to
assess effectiveness, rather than efficacy. The PIPP tool is
validated for infants of all gestations and takes gestational
age into account for scoring. However, higher or lower
PIPP scores have been described in smaller infants
[23,24]. Fifteen participants in our trial were less than 28
weeks gestation, thus the confounding effect was likely
insignificant.
Finally, a venipuncture is more than a simple skin punc-
ture. Infants are restrained, a tourniquet is applied and the
procedure can last up to several minutes. It has been dem-
onstrated in previous studies that handling and immobi-
lization lead to behavioural and physiological reactivity
[29,30]. Thus, the skin puncture alone is unlikely to be the
only stressful (or painful) event during a venipuncture.
Conclusion
Tetracaine did not significantly decrease procedural pain
in infants undergoing a venipuncture, when used in a set-
ting where sucrose is routinely used for procedural pain.
Further studies, comparing sucrose, tetracaine and the two
interventions combined are warranted, to better delineate
which strategy is best to prevent pain associated with a
venipuncture.
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Post-hoc analysis, stratified by use of sucrose Figure 2
Post-hoc analysis, stratified by use of sucrose.
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